KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other financing activities (2018 - 2025)

Historic Other financing activities for Rigel Pharmaceuticals (RIGL) over the last 10 years, with Q3 2025 value amounting to $4.3 million.

  • Rigel Pharmaceuticals' Other financing activities rose 260316.46% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 57390.86%. This contributed to the annual value of $2.0 million for FY2024, which is 8722.59% up from last year.
  • Rigel Pharmaceuticals' Other financing activities amounted to $4.3 million in Q3 2025, which was up 260316.46% from $418000.0 recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Other financing activities registered a high of $4.3 million during Q3 2025, and its lowest value of $1000.0 during Q1 2023.
  • Moreover, its 5-year median value for Other financing activities was $486000.0 (2023), whereas its average is $852941.2.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Other financing activities plummeted by 9989.36% in 2023, and later skyrocketed by 880000.0% in 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Other financing activities (Quarter) stood at $1.1 million in 2021, then plummeted by 44.79% to $599000.0 in 2022, then fell by 18.86% to $486000.0 in 2023, then soared by 201.44% to $1.5 million in 2024, then skyrocketed by 191.54% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $418000.0 for Q2 2025, and $484000.0 during Q1 2025.